VIVUS (VVUS) Shares Up 4.1%

VIVUS, Inc. (NASDAQ:VVUS)’s share price shot up 4.1% during trading on Thursday . The stock traded as high as $0.53 and last traded at $0.51. 1,032,000 shares were traded during trading, an increase of 42% from the average session volume of 728,808 shares. The stock had previously closed at $0.49.

Separately, ValuEngine lowered VIVUS from a “buy” rating to a “hold” rating in a research note on Friday, September 1st.

The stock has a market cap of $52.24, a P/E ratio of 1.47 and a beta of 0.77. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86.

VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.07. The firm had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) earnings per share. analysts forecast that VIVUS, Inc. will post -0.32 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in VVUS. AJO LP purchased a new position in shares of VIVUS during the second quarter valued at $3,329,000. OxFORD Asset Management LLP grew its stake in VIVUS by 58.2% in the second quarter. OxFORD Asset Management LLP now owns 929,511 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 341,976 shares during the last quarter. Russell Investments Group Ltd. grew its stake in VIVUS by 166.2% in the third quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 246,927 shares during the last quarter. Macquarie Group Ltd. purchased a new position in VIVUS in the third quarter valued at about $192,000. Finally, Northern Trust Corp grew its stake in VIVUS by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 39,473 shares during the last quarter. Hedge funds and other institutional investors own 31.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/12/23/vivus-vvus-shares-up-4-1.html.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit